Literature DB >> 2568681

Pathogenesis of cardiovascular alterations in dogs treated with minoxidil.

G M Mesfin1, R C Piper, D W DuCharme, R G Carlson, S J Humphrey, G R Zins.   

Abstract

Minoxidil and other potent vasodilators cause coronary arterial injury, right atrial hemorrhagic lesions, and subendocardial necrosis in dogs. This paper discusses the pathogenesis of coronary arterial and right atrial lesions associated with minoxidil in the dog. Acute coronary vascular injury characterized by segmental medial hemorrhage and necrosis and perivascular inflammation occurred only during the first few days of treatment, after which tolerance to further acute injury developed. At 30 d or more of treatment, coronary vascular injury was characterized by perivascular fibrosis rarely attended by medial distortion or hyperplasia and subintimal thickening, changes consistent with responses to previous injury. Right atrial hemorrhagic lesions, unlike coronary vascular injury, often became progressively more extensive with continued treatment. At 3 d, atrial hemorrhage and inflammation were confined to the subepicardium of the right atrium, evidently around affected subepicardial branches of the right coronary artery. At 30 d, fibrovascular proliferative right atrial lesions (granulation tissue with evidence of continual hemorrhage) extended from the epicardium to the myocardium, with eventual replacement of the atrial wall by mature connective tissue at 1 yr of treatment. Minoxidil-induced cardiovascular lesions were not prevented by treatment with a beta-blocker (propranolol), or an alpha-blocker (dibenzylene), or by sympathetic neural activity suppression (surgical sympathectomy or constant carotid sinus nerve stimulation), suggesting that the sympathetic response to the pharmacologic activity of minoxidil was not responsible for the induction of the cardiovascular lesions. Minoxidil-related vascular lesions were confined to the most pharmacologically responsive segment of the arterial system, the coronary arteries, suggesting that medial injury may have been associated with tensile changes in the arterial wall.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2568681     DOI: 10.1177/019262338901700113

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  5 in total

1.  Tissue-engineered blood vessels as promising tools for testing drug toxicity.

Authors:  George A Truskey; Cristina E Fernandez
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-05-31       Impact factor: 4.481

2.  Endothelin receptor subtype distribution predisposes coronary arteries to damage.

Authors:  C S Louden; P Nambi; M A Pullen; R A Thomas; L A Tierney; H A Solleveld; L W Schwartz
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

3.  Evaluation of von Willebrand factor and von Willebrand factor propeptide in models of vascular endothelial cell activation, perturbation, and/or injury.

Authors:  David A Brott; Anne Katein; Heath Thomas; Michael Lawton; Robert R Montgomery; Rudy J Richardson; Calvert S Louden
Journal:  Toxicol Pathol       Date:  2014-02-04       Impact factor: 1.902

4.  Human Vascular Wall Microfluidic Model for Preclinical Evaluation of Drug-Induced Vascular Injury.

Authors:  Erik Ersland; Neven Ebrahim; Olive Mwizerwa; Takahiro Oba; Keisuke Oku; Masafumi Nishino; Daichi Hikimoto; Hayato Miyoshi; Kimihiko Tomotoshi; Omid Rahmanian; Emmanuel Ekwueme; Craig Neville; Cathryn Sundback
Journal:  Tissue Eng Part C Methods       Date:  2022-02       Impact factor: 3.056

5.  Successful drug development despite adverse preclinical findings part 2: examples.

Authors:  Robert A Ettlin; Junji Kuroda; Stephanie Plassmann; Makoto Hayashi; David E Prentice
Journal:  J Toxicol Pathol       Date:  2010-12-16       Impact factor: 1.628

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.